Literature DB >> 1651945

High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues.

R M Shepard1, G S Duthu, R A Ferraina, M A Mullins.   

Abstract

High-performance liquid chromatographic methods using reversed-phase chromatography and electrochemical detection have been developed for the quantitation of azithromycin in serum and tissues of laboratory animals and humans. Serum sample preparation involved addition of internal standard, alkalinization, and solvent extraction. Tissue sample preparation involved Polytron homogenization in acetonitrile containing internal standard, evaporation of the supernatant, alkalinization of the residue, and solvent extraction. Serum samples were chromatographed on an alkylphenyl-bonded silica column eluted with pH 6.8-7.2 mobile phase with a dual-electrode coulometric detector operated in the oxidative screen mode. Serum and tissue samples were chromatographed on a gamma RP-1 alumina column with pH 11 mobile phase with a glassy carbon amperometric detector. Recovery of azithromycin was 87% from serum and 85% from tissues. Linear standard curves were prepared in serum over two concentration ranges (0.01-0.20 and 0.20-2.0 micrograms/ml) and in tissues over several concentration ranges (0.1-2, 1-10, 10-100, and 100-1000 micrograms/g). In serum and tissues, intra- and inter-assay precision ranged from 1 to 8% and 4 to 11%, respectively. The tissue assay has been applied to liver, kidney, lung, spleen, muscle, fat, brain, tonsil, lymph nodes, eye, prostate and other urological tissues, and gynecological tissues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651945     DOI: 10.1016/0378-4347(91)80393-q

Source DB:  PubMed          Journal:  J Chromatogr


  19 in total

1.  Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.

Authors:  R Hafner; J Bethel; H C Standiford; S Follansbee; D L Cohn; R E Polk; L Mole; R Raasch; P Kumar; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  The use of gastrointestinal intubation studies for controlled release development.

Authors:  Steven C Sutton
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

3.  Concentration of azithromycin in human prostatic tissue.

Authors:  G Foulds; P Madsen; C Cox; R Shepard; R Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

4.  Safety, toleration, and pharmacokinetics of intravenous azithromycin.

Authors:  D R Luke; G Foulds; S F Cohen; B Levy
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  Concentrations of azithromycin in human tonsillar tissue.

Authors:  G Foulds; K H Chan; J T Johnson; R M Shepard; R B Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

6.  Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.

Authors:  K A Rodvold; M H Gotfried; L H Danziger; R J Servi
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry.

Authors:  C Wenisch; B Parschalk; K Zedtwitz-Liebenstein; A Weihs; I el Menyawi; W Graninger
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

8.  Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

Authors:  R Malinverni; C C Kuo; L A Campbell; A Lee; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Pharmacokinetic study of azithromycin with fluconazole and cotrimoxazole (trimethoprim-sulfamethoxazole) in healthy volunteers.

Authors:  G W Amsden; G Foulds; K Thakker
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

10.  In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii.

Authors:  F G Araujo; R M Shepard; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-06       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.